More Than 600 NCCN Chemotherapy Order Templates Now Available from NCCN to Enhance Patient Safety
NCCN launched a complete library of NCCN Chemotherapy Order Templates, including more than 600 peer-reviewed and evidence-based chemotherapy regimens to enhance patient safety by standardizing care.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has launched a complete library of NCCN Chemotherapy Order Templates (NCCN Templates™) for the top 13 most frequently occurring tumor types. The NCCN Templates now include more than 600 peer-reviewed and evidence-based chemotherapy regimens for clinicians. New to the library are NCCN Templates™ for esophageal, gastric, ovarian, pancreatic, and rectal cancers, multiple myeloma, and diffuse large B-cell lymphoma. These highly anticipated additions to the NCCN Templates are designed to enhance patient safety by helping clinicians standardize patient care, reduce medication errors, and anticipate and manage adverse events.
The NCCN is pleased to make available this set of more than 600 NCCN Chemotherapy Order Templates for the most frequently occurring tumor types. Additional templates are available online at NCCN.org, said William T. McGivney, PhD, Chief Executive Officer, NCCN. NCCN believes that these comprehensive chemotherapy templates will serve to improve the safety of administration and the benefit derived by patients. The set of NCCN Chemotherapy Order Templates represents yet another in a continuum of interrelated NCCN scientific, evaluative, information products that facilitate improved decision-making on behalf of patients whom we serve.
The NCCN Templates include valuable guidance for clinicians regarding indications, doses, schedules and routes of administration, monitoring parameters, and safety instructions for chemotherapy. Management of immunotherapies and the corresponding supportive agents and instructions for self-administered chemotherapeutic agents are also provided. All information in the NCCN Templates is derived from the recommendations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), recognized as the standard for clinical policy in the oncology community, and the NCCN Drugs & Biologics Compendium (NCCN Compendium™), resources already widely recognized as the standards of clinical practice and policy. Currently, the NCCN Compendium™ is recognized by the Centers for Medicare & Medicaid Services (CMS) and UnitedHealthcare, along with other insurers, as an authoritative reference for oncology coverage policy.
The NCCN Templates are a continuously updated subscription product from NCCN and can be purchased via NCCN.org. NCCN will continue developing the library of chemotherapy order templates to improve the safe and effective use of drugs and biologics in cancer care.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital